About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Nanobiotix announces trading resumption of its ordinary shares on Euronext Paris
Nanobiotix announces pricing of global offering and approval to list on nasdaq global select market
11 December 2020
Nanobiotix announces closing of the global offering and full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of global offering to $113.3 million
15 December 2020
Nanobiotix announces trading resumption of its ordinary shares on Euronext Paris
Published by
Julie Ficheux
on
11 December 2020
No translations available for this page
